U.S. markets open in 51 minutes
  • S&P Futures

    4,524.25
    +15.75 (+0.35%)
     
  • Dow Futures

    34,244.00
    +242.00 (+0.71%)
     
  • Nasdaq Futures

    15,840.50
    -29.25 (-0.18%)
     
  • Russell 2000 Futures

    2,170.20
    +23.90 (+1.11%)
     
  • Crude Oil

    65.64
    +0.07 (+0.11%)
     
  • Gold

    1,776.00
    -8.30 (-0.47%)
     
  • Silver

    22.39
    +0.05 (+0.21%)
     
  • EUR/USD

    1.1337
    +0.0014 (+0.12%)
     
  • 10-Yr Bond

    1.4170
    -0.0170 (-1.19%)
     
  • Vix

    29.68
    +2.49 (+9.16%)
     
  • GBP/USD

    1.3320
    +0.0043 (+0.32%)
     
  • USD/JPY

    112.8600
    +0.0800 (+0.07%)
     
  • BTC-USD

    56,301.59
    -1,359.76 (-2.36%)
     
  • CMC Crypto 200

    1,435.86
    -33.22 (-2.26%)
     
  • FTSE 100

    7,104.09
    -64.59 (-0.90%)
     
  • Nikkei 225

    27,753.37
    -182.25 (-0.65%)
     

What Type Of Shareholders Own The Most Number of Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares?

  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

A look at the shareholders of Adaptimmune Therapeutics plc (NASDAQ:ADAP) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Companies that used to be publicly owned tend to have lower insider ownership.

Adaptimmune Therapeutics isn't enormous, but it's not particularly small either. It has a market capitalization of US$818m, which means it would generally expect to see some institutions on the share registry. Taking a look at our data on the ownership groups (below), it seems that institutional investors have bought into the company. Let's take a closer look to see what the different types of shareholders can tell us about Adaptimmune Therapeutics.

Check out our latest analysis for Adaptimmune Therapeutics

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Adaptimmune Therapeutics?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

We can see that Adaptimmune Therapeutics does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Adaptimmune Therapeutics, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

It would appear that 6.3% of Adaptimmune Therapeutics shares are controlled by hedge funds. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Our data shows that New Enterprise Associates, Inc. is the largest shareholder with 11% of shares outstanding. For context, the second largest shareholder holds about 6.7% of the shares outstanding, followed by an ownership of 6.3% by the third-largest shareholder.

After doing some more digging, we found that the top 20 have the combined ownership of 50% in the company, suggesting that no single shareholder has significant control over the company.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

Insider Ownership Of Adaptimmune Therapeutics

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Our most recent data indicates that insiders own some shares in Adaptimmune Therapeutics plc. As individuals, the insiders collectively own US$13m worth of the US$818m company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling.

General Public Ownership

The general public holds a 46% stake in Adaptimmune Therapeutics. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Equity Ownership

Private equity firms hold a 11% stake in Adaptimmune Therapeutics. This suggests they can be influential in key policy decisions. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Adaptimmune Therapeutics better, we need to consider many other factors. For example, we've discovered 5 warning signs for Adaptimmune Therapeutics (1 makes us a bit uncomfortable!) that you should be aware of before investing here.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.